Sonoma Pharmaceuticals (SNOA) Common Equity (2011 - 2025)

Sonoma Pharmaceuticals' Common Equity history runs 15 years deep, the most recent figure standing at $3.4 million for Q4 2025.

• In Q4 2025, Common Equity fell 29.53% year-over-year to $3.4 million; the TTM figure through Dec 2025 stood at $3.4 million (down 29.53% YoY), while the FY2025 annual figure was $4.4 million, down 28.12% from the prior year.
• Common Equity was $3.4 million for Q4 2025 at Sonoma Pharmaceuticals, down from $3.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $11.5 million in Q3 2021 to a low of $3.4 million in Q4 2025.
• Historically, Common Equity has averaged $6.3 million across 5 years, with a median of $5.6 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Common Equity slumped 56.67% in 2021, then surged 72.24% in 2022.
• A 5-year view of Common Equity shows it stood at $11.2 million in 2021, then slumped by 50.23% to $5.6 million in 2022, then increased by 20.38% to $6.7 million in 2023, then fell by 27.23% to $4.9 million in 2024, then slipped by 29.53% to $3.4 million in 2025.
• The last three Common Equity figures came in at $3.4 million (Q4 2025), $3.8 million (Q3 2025), and $4.1 million (Q2 2025), per Business Quant data.